Please cite this article as: Poromaa IS, Segebladh B. Adverse mood symptoms with oral contraceptives. Acta Obstet Gynecol Scand 2012;91: DOI:10.1111/j.1600-0412.2011.01333.x.
Adverse mood symptoms with oral contraceptives
Article first published online: 19 JAN 2012
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2012 Nordic Federation of Societies of Obstetrics and Gynecology
Acta Obstetricia et Gynecologica Scandinavica
Volume 91, Issue 4, pages 420–427, April 2012
How to Cite
POROMAA, I. S. and SEGEBLADH, B. (2012), Adverse mood symptoms with oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica, 91: 420–427. doi: 10.1111/j.1600-0412.2011.01333.x
- Issue published online: 20 MAR 2012
- Article first published online: 19 JAN 2012
- Accepted manuscript online: 2 DEC 2011 06:12AM EST
- Received: 19 May 2011, Accepted: 23 November 2011
- mood changes;
- menstrual cycle
In spite of combined oral contraceptives (COCs) having been available for more than 50 years, surprisingly little is known about the prevalence of truly COC-related adverse mood symptoms and about the underlying biological mechanisms of proposed changes in mood and affect. Precise estimates of COC-related adverse mood symptoms are not available due to the lack of placebo-controlled trials. In prospective trials the frequency of women who report deteriorated mood or deteriorated emotional well-being varies between 4 and 10%, but it can be assumed that the causal relation in these prevalence rates is overestimated. Adverse mood symptoms and somatic symptoms are most pronounced during the pill-free interval of the treatment cycles, but whether extended COC regimens would be more favorable in this respect is not known. COCs with anti-androgenic progestagens, such as drospirenone and desogestrel, appear more favorable in terms of mood symptoms than progestagens with a more androgenic profile. Available data suggest that lower doses of ethinylestradiol could be beneficial.